Published: May 9th 2024 | Updated: May 21st 2024
FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors
Published: September 6th 2024 | Updated: September 12th 2024
Future Directions for Type 2 Inflammation Management
Published: September 6th 2024 | Updated: September 12th 2024
Addressing Unmet Needs and Emerging Agents
Published: August 30th 2024 | Updated: September 12th 2024
Biomarkers as Tools in Management of Type 2 Inflammation
Published: August 30th 2024 | Updated: September 12th 2024
Strategies to Manage Type 2 Inflammation in Respiratory Diseases
Published: September 3rd 2024 | Updated: September 12th 2024
PCOC 2024 Promises to Hit All the High Notes